HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

INVEST - EVOTECDETERMS & CONDITIONSCORPORATE GOVERNANCEFINANCIAL

REPORTS

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

PIPELINE OF PRODUCT OPPORTUNITIES Constantly growing pipeline of product opportunities. EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and

royalties.

LOCATIONS - EVOTEC

Goettingen, Germany. Evotec International GmbH is a subsidiary of Evotec and situated right in the middle of Germany in Goettingen. This city is well known for its high-ranking science and research institutions, the fame of which are enhanced by more than 40 Nobel

Prize Winners.

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders TARGET IDENTIFICATION AND VALIDATION Cellular target identification is the crucial step to enable further drug optimisation and development. Evotec Cellular Target Profiling™ is a powerful technology to identify specific cellular compound targets in lysates from any cell type or tissue. Evotec’s chemical proteomics offering further comprises photoaffinity labelling for BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

PERKINELMER TO ACQUIRE EVOTEC TECHNOLOGIES Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) yesterday evening announced that PerkinElmer Inc. (NYSE: PKI) signed a definitive agreement to acquire Evotec Technologies GmbH in a cash transaction valued at approximately EUR 23 million. Evotec Technologies is a majority owned subsidiary of Evotec

AG, which

HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

INVEST - EVOTECDETERMS & CONDITIONSCORPORATE GOVERNANCEFINANCIAL

REPORTS

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

PIPELINE OF PRODUCT OPPORTUNITIES Constantly growing pipeline of product opportunities. EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and

royalties.

LOCATIONS - EVOTEC

Goettingen, Germany. Evotec International GmbH is a subsidiary of Evotec and situated right in the middle of Germany in Goettingen. This city is well known for its high-ranking science and research institutions, the fame of which are enhanced by more than 40 Nobel

Prize Winners.

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders TARGET IDENTIFICATION AND VALIDATION Cellular target identification is the crucial step to enable further drug optimisation and development. Evotec Cellular Target Profiling™ is a powerful technology to identify specific cellular compound targets in lysates from any cell type or tissue. Evotec’s chemical proteomics offering further comprises photoaffinity labelling for BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

PERKINELMER TO ACQUIRE EVOTEC TECHNOLOGIES Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) yesterday evening announced that PerkinElmer Inc. (NYSE: PKI) signed a definitive agreement to acquire Evotec Technologies GmbH in a cash transaction valued at approximately EUR 23 million. Evotec Technologies is a majority owned subsidiary of Evotec

AG, which

ABOUT - EVOTEC

Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and make them accessible to patients

worldwide.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business. DRUG DISCOVERY SERVICES Evotec offers services and alliances based on its state-of-the-art technology platform and a broad range of integrated capabilities spanning the drug discovery process. Evotec differentiates itself based on a strong track record in drug discovery, scientists with many years experience in the industry and an innovative technology

platform.

EVOTEC WORLDWIDE

Evotec (US) Inc. 33 Business Park Drive #6 Branford, CT 06405 U.S.A. Get directions. T +1 650.228.1400. F +1 650.228.0137. info@evotec.com. Evotec International GmbH. Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany info@evotec.com Postal address Cologne site: Gebäude S20 Nattermannallee 1 50829 Köln, Germany.

R&D PROJECTS

R&D projects. Within our internal EVT Innovate R&D portfolio, we are executing drug discovery programmes in various ways: Internal/proprietary projects, fully funded by Evotec. Programmes funded through external investors, foundations or public grants.

HIT IDENTIFICATION

Hit identification. Evotec has a strong expertise in hit identification and can support its clients screening campaigns through multiple platforms including virtual, biochemical, biophysical, cell and phenotypic based screening with high-throughput capabilities. For screening campaigns, Evotec has the flexibility to screen large client

compound

IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders TARGET IDENTIFICATION AND VALIDATION Cellular target identification is the crucial step to enable further drug optimisation and development. Evotec Cellular Target Profiling™ is a powerful technology to identify specific cellular compound targets in lysates from any cell type or tissue. Evotec’s chemical proteomics offering further comprises photoaffinity labelling for AUTOBAHN LABS INCUBATOR ANNOUNCES PARTNERSHIP WITH COLD Expansion to East Coast validates Autobahn Labs’ novel incubator model Palo Alto, CA, USA, 07 June 2021: Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). PERKINELMER TO ACQUIRE EVOTEC TECHNOLOGIES Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) yesterday evening announced that PerkinElmer Inc. (NYSE: PKI) signed a definitive agreement to acquire Evotec Technologies GmbH in a cash transaction valued at approximately EUR 23 million. Evotec Technologies is a majority owned subsidiary of Evotec

AG, which

HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

PIPELINE OF PRODUCT OPPORTUNITIES Constantly growing pipeline of product opportunities. EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and

royalties.

JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. INTEGRATED PRE-CLINICAL DEVELOPMENT Integrated pre-clinical development. The Evotec Pre-clinical Development team can perform the full spectrum of pre-clinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client’s requirements. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC EXPANDS OXFORDSHIRE SITE INTO A FULLY-INTEGRATED R About Dorothy Crowfoot Hodgkin. Dorothy Hodgkin (née Crowfoot) was born in Cairo in 1910. She became interested in chemistry and in crystals at about the age of 10, and she became one of two girls who were allowed to join the boys doing chemistry at her school. EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

PIPELINE OF PRODUCT OPPORTUNITIES Constantly growing pipeline of product opportunities. EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and

royalties.

JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. INTEGRATED PRE-CLINICAL DEVELOPMENT Integrated pre-clinical development. The Evotec Pre-clinical Development team can perform the full spectrum of pre-clinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client’s requirements. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC EXPANDS OXFORDSHIRE SITE INTO A FULLY-INTEGRATED R About Dorothy Crowfoot Hodgkin. Dorothy Hodgkin (née Crowfoot) was born in Cairo in 1910. She became interested in chemistry and in crystals at about the age of 10, and she became one of two girls who were allowed to join the boys doing chemistry at her school. EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

EVOTEC GENE THERAPY

Evotec GT. Gene therapy is a rapidly evolving modality enabling curative treatments for a broad range of diseases. This approach involves insertion of nucleic acid into the nuclear genome via a genetically engineered vector. Evotec’s dedicated gene therapy site, Evotec GT, is located in Austria and provides a team of experts to

cover the full

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

EVOTEC SE FISCAL YEAR 2020 RESULTS: GAINING SPEED ON THE FINANCIAL GUIDANCE 2021 – CONTINUED STRONG GROWTH. In 2021, Evotec expects Group revenues to grow in a range of € 550–570 m. At unchanged exchange rates compared to 2020, this range is € 565 m to

€ 585 m.

CHEMISTRY - EVOTEC

Synthesis, scale-up and synthetic route development. At the foundation of Evotec’s medicinal chemistry group is a talented and industry-experienced team of >200 synthetic organic chemists supporting medicinal chemistry-driven projects, focused library preparation, literature, building blocks, route developmentand

scale-up synthesis.

IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders INTEGRATED PRE-CLINICAL DEVELOPMENT Integrated pre-clinical development. The Evotec Pre-clinical Development team can perform the full spectrum of pre-clinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client’s requirements. AUTOBAHN LABS INCUBATOR ANNOUNCES PARTNERSHIP WITH COLD Expansion to East Coast validates Autobahn Labs’ novel incubator model Palo Alto, CA, USA, 07 June 2021: Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

PIPELINE OF PRODUCT OPPORTUNITIES Constantly growing pipeline of product opportunities. EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and

royalties.

JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. INTEGRATED PRE-CLINICAL DEVELOPMENT Integrated pre-clinical development. The Evotec Pre-clinical Development team can perform the full spectrum of pre-clinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client’s requirements. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

PIPELINE OF PRODUCT OPPORTUNITIES Constantly growing pipeline of product opportunities. EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and

royalties.

JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. INTEGRATED PRE-CLINICAL DEVELOPMENT Integrated pre-clinical development. The Evotec Pre-clinical Development team can perform the full spectrum of pre-clinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client’s requirements. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

EVOTEC GENE THERAPY

Evotec GT. Gene therapy is a rapidly evolving modality enabling curative treatments for a broad range of diseases. This approach involves insertion of nucleic acid into the nuclear genome via a genetically engineered vector. Evotec’s dedicated gene therapy site, Evotec GT, is located in Austria and provides a team of experts to

cover the full

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

EVOTEC SE FISCAL YEAR 2020 RESULTS: GAINING SPEED ON THE FINANCIAL GUIDANCE 2021 – CONTINUED STRONG GROWTH. In 2021, Evotec expects Group revenues to grow in a range of € 550–570 m. At unchanged exchange rates compared to 2020, this range is € 565 m to

€ 585 m.

CHEMISTRY - EVOTEC

Synthesis, scale-up and synthetic route development. At the foundation of Evotec’s medicinal chemistry group is a talented and industry-experienced team of >200 synthetic organic chemists supporting medicinal chemistry-driven projects, focused library preparation, literature, building blocks, route developmentand

scale-up synthesis.

IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders INTEGRATED PRE-CLINICAL DEVELOPMENT Integrated pre-clinical development. The Evotec Pre-clinical Development team can perform the full spectrum of pre-clinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client’s requirements. AUTOBAHN LABS INCUBATOR ANNOUNCES PARTNERSHIP WITH COLD Expansion to East Coast validates Autobahn Labs’ novel incubator model Palo Alto, CA, USA, 07 June 2021: Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

INVEST - EVOTECDETERMS & CONDITIONSCORPORATE GOVERNANCEFINANCIAL

REPORTS

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business. DRUG DISCOVERY SERVICES Evotec offers services and alliances based on its state-of-the-art technology platform and a broad range of integrated capabilities spanning the drug discovery process. Evotec differentiates itself based on a strong track record in drug discovery, scientists with many years experience in the industry and an innovative technology

platform.

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

PHARMA PARTNERSHIPS

Pharma partnerships. Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to

potential

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

INVEST - EVOTECDETERMS & CONDITIONSCORPORATE GOVERNANCEFINANCIAL

REPORTS

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business. DRUG DISCOVERY SERVICES Evotec offers services and alliances based on its state-of-the-art technology platform and a broad range of integrated capabilities spanning the drug discovery process. Evotec differentiates itself based on a strong track record in drug discovery, scientists with many years experience in the industry and an innovative technology

platform.

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

PHARMA PARTNERSHIPS

Pharma partnerships. Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to

potential

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTEC

Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

INVEST - EVOTEC

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

EVOTEC SE FISCAL YEAR 2020 RESULTS: GAINING SPEED ON THE FINANCIAL GUIDANCE 2021 – CONTINUED STRONG GROWTH. In 2021, Evotec expects Group revenues to grow in a range of € 550–570 m. At unchanged exchange rates compared to 2020, this range is € 565 m to

€ 585 m.

IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders AUTOBAHN LABS INCUBATOR ANNOUNCES PARTNERSHIP WITH COLD Expansion to East Coast validates Autobahn Labs’ novel incubator model Palo Alto, CA, USA, 07 June 2021: Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). BREAKPOINT THERAPEUTICS Breakpoint Therapeutics. In July 2019, Evotec announced the formation of the spin-off company Breakpoint Therapeutics GmbH, a virtual biotech company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with

DNA

CORPORATE GOVERNANCE The German Corporate Governance Code (the “Code”) presents essential statutory regulations for the management and supervision (governance) of German listed companies and contains internationally and nationally recognised standards for good and responsible governance. The Code aims at making the German Corporate Governance

system transparent

BIOMARKERS - EVOTEC

Biomarker discovery, development and validation is a key discipline to de-risk (later stage) drug discovery and development. Biomarkers are defined as quantifiable biological parameters that can monitor the response of the body to a (disease modulating) agent, allow for diagnosis of a disease, or monitor disease progression and different sub-types of patients (potential responders vs non HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

INVEST - EVOTECDETERMS & CONDITIONSCORPORATE GOVERNANCEFINANCIAL

REPORTS

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

DRUG DISCOVERY SERVICES Evotec offers services and alliances based on its state-of-the-art technology platform and a broad range of integrated capabilities spanning the drug discovery process. Evotec differentiates itself based on a strong track record in drug discovery, scientists with many years experience in the industry and an innovative technology

platform.

PHARMA PARTNERSHIPS

Pharma partnerships. Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to

potential

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

INVEST - EVOTECDETERMS & CONDITIONSCORPORATE GOVERNANCEFINANCIAL

REPORTS

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business. DRUG DISCOVERY SERVICES Evotec offers services and alliances based on its state-of-the-art technology platform and a broad range of integrated capabilities spanning the drug discovery process. Evotec differentiates itself based on a strong track record in drug discovery, scientists with many years experience in the industry and an innovative technology

platform.

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

PHARMA PARTNERSHIPS

Pharma partnerships. Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to

potential

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTEC

Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

INVEST - EVOTEC

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

EVOTEC SE FISCAL YEAR 2020 RESULTS: GAINING SPEED ON THE FINANCIAL GUIDANCE 2021 – CONTINUED STRONG GROWTH. In 2021, Evotec expects Group revenues to grow in a range of € 550–570 m. At unchanged exchange rates compared to 2020, this range is € 565 m to

€ 585 m.

AUTOBAHN LABS INCUBATOR ANNOUNCES PARTNERSHIP WITH COLD Expansion to East Coast validates Autobahn Labs’ novel incubator model Palo Alto, CA, USA, 07 June 2021: Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders BREAKPOINT THERAPEUTICS Breakpoint Therapeutics. In July 2019, Evotec announced the formation of the spin-off company Breakpoint Therapeutics GmbH, a virtual biotech company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with

DNA

CORPORATE GOVERNANCE The German Corporate Governance Code (the “Code”) presents essential statutory regulations for the management and supervision (governance) of German listed companies and contains internationally and nationally recognised standards for good and responsible governance. The Code aims at making the German Corporate Governance

system transparent

BIOMARKERS - EVOTEC

Biomarker discovery, development and validation is a key discipline to de-risk (later stage) drug discovery and development. Biomarkers are defined as quantifiable biological parameters that can monitor the response of the body to a (disease modulating) agent, allow for diagnosis of a disease, or monitor disease progression and different sub-types of patients (potential responders vs non HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

INVEST - EVOTEC

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. DRUG DISCOVERY SERVICES Evotec offers services and alliances based on its state-of-the-art technology platform and a broad range of integrated capabilities spanning the drug discovery process. Evotec differentiates itself based on a strong track record in drug discovery, scientists with many years experience in the industry and an innovative technology

platform.

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

PHARMA PARTNERSHIPS

Pharma partnerships. Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to

potential

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTECPHARMA PARTNERSHIPSINVESTCAREERIR EVENTSTARGET IDENTIFICATION AND VALIDATIONTHERAPEUTIC AREAS Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

INVEST - EVOTEC

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. DRUG DISCOVERY SERVICES Evotec offers services and alliances based on its state-of-the-art technology platform and a broad range of integrated capabilities spanning the drug discovery process. Evotec differentiates itself based on a strong track record in drug discovery, scientists with many years experience in the industry and an innovative technology

platform.

BRIDGES - EVOTEC

beLAB1407. In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of

Evotec’s

PHARMA PARTNERSHIPS

Pharma partnerships. Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to

potential

FINANCIAL REPORTS

Financial Reports. Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations. EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON The strategic alliance will also have access to targets from the recently formed partnership between Celmatix and Evotec. Celmatix is the world leader in big data-driven target discovery focused on fertility and women’s health. “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with

several serious

EVOTEC AND CELGENE FURTHER EXPAND IPSC COLLABORATION Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify

disease-modifying

HOME - EVOTEC

Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, 11 May 2021. Evotec SE today announced the financial results and corporate updates for the first

quarter 2021.

CAREER - EVOTEC

Evotec is a science-driven, dynamic company with the feel and excitement of a high-growth enterprise. With over 3,500 employees in Europe and the USA, however, we are still small enough for everyone to play an integral role and to truly have a positive impact on the success of our business.

INVEST - EVOTEC

Our equity story - 5 reasons to invest in Evotec. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. JUST - EVOTEC BIOLOGICS - EVOTEC J.Design. J.DESIGN is an in-house, integrated technology platform. Utilising J.DESIGN Just - Evotec Biologics accelerates development and provides superior manufacturing process control for higher quality molecules at the lowest possible cost. At the core of J.DESIGN is a common data management system that centralises and integrates the

highly

EVOTEC SE FISCAL YEAR 2020 RESULTS: GAINING SPEED ON THE FINANCIAL GUIDANCE 2021 – CONTINUED STRONG GROWTH. In 2021, Evotec expects Group revenues to grow in a range of € 550–570 m. At unchanged exchange rates compared to 2020, this range is € 565 m to

€ 585 m.

BIOANALYSIS

Bioanalysis. Evotec has a breadth of experience in regulated bioanalysis for small molecules and bio-therapeutics of any size: peptides, recombinant proteins, monoclonal antibodies, oligonucleotides, as well as anti-drug antibodies, vaccines, cell

therapies and gene

AUTOBAHN LABS INCUBATOR ANNOUNCES PARTNERSHIP WITH COLD Expansion to East Coast validates Autobahn Labs’ novel incubator model Palo Alto, CA, USA, 07 June 2021: Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). IN VIVO PHARMACOLOGY In vivo Pharmacology for Inflammation and Immunology. Evotec’s experienced immunology & inflammation in vivo team has an established and proven track record. The team has contributed to the discovery and development of multiple pre-clinical and clinical candidates and is currently working on >12 immunology and inflammation programmes in the areas of inflammation, autoimmune disorders CORPORATE GOVERNANCE The German Corporate Governance Code (the “Code”) presents essential statutory regulations for the management and supervision (governance) of German listed companies and contains internationally and nationally recognised standards for good and responsible governance. The Code aims at making the German Corporate Governance

system transparent

BIOMARKERS - EVOTEC

Biomarker discovery, development and validation is a key discipline to de-risk (later stage) drug discovery and development. Biomarkers are defined as quantifiable biological parameters that can monitor the response of the body to a (disease modulating) agent, allow for diagnosis of a disease, or monitor disease progression and different sub-types of patients (potential responders vs non